Travere Therapeutics

Travere Therapeutics (TVTX) is the lead sponsor of 8 active clinical trials listed on ClinicalTrials.gov^[5], including 4 Phase 3^[1], 2 Phase 2^[2], 1 Phase 1^[3], 1 Phase 4^[4].

Trial NCT06247085^[6] evaluates Pegtibatinase in Homocystinuria with a target enrollment of 70 participants. Trial NCT03762850^[7] evaluates sparsentan in Immunoglobulin A Nephropathy with a target enrollment of 406 participants. Trial NCT03493685^[8] evaluates sparsentan in Focal Segmental Glomerulosclerosis with a target enrollment of 371 participants.

TVTX has 4 Form 4 insider filings recorded at the SEC in the past 30 days^[9].